Alimera Sciences Inc represents a commitment to improving the lives of patients with retinal diseases. The company is dedicated to developing and commercializing innovative prescription products that address the unmet medical needs in ophthalmology. Alimera Sciences focuses on the development of sustained-release treatments, such as ILUVIEN®, which is designed to provide long-term reduction of vision loss associated with diabetic macular edema. With a patient-centric approach, Alimera Sciences strives to enhance visual outcomes and quality of life for individuals worldwide. The company's corporate philosophy emphasizes scientific excellence, ethical behavior, and a dedication to advancing eye care through research and development.

Alimera Sciences Inc is primarily present in the United States, Europe, and the Middle East.

Alimera Sciences Inc has achieved significant milestones since its inception. Notably, the company has successfully developed and commercialized ILUVIEN, a sustained-release intravitreal implant for the treatment of diabetic macular edema (DME). This innovative product has been approved by regulatory authorities in various countries, including Europe and the United States. Additionally, Alimera Sciences Inc has expanded its market reach through strategic partnerships and collaborations with influential pharmaceutical companies. The company's commitment to ongoing research and development has led to advancements in ocular drug delivery systems, positioning Alimera Sciences Inc as a leading player in the ophthalmic pharmaceutical industry.

Alimera Sciences Inc. is a pharmaceutical company established in 2003 and headquartered in Atlanta, Georgia. It specializes in developing and commercializing prescription ophthalmology products for the treatment of retinal diseases. Alimera Sciences Inc. is primarily known for its flagship product, ILUVIEN®, which is an injectable steroid implant used for the treatment of diabetic macular edema (DME) in patients who have been previously treated but have not responded adequately to other therapies. With its innovative products and focus on retinal diseases, Alimera Sciences Inc. continues to make significant contributions to the healthcare industry.

The main competitors of Alimera Sciences Inc in the market are pharmaceutical companies that specialize in ophthalmology and the treatment of various eye diseases. Some of the prominent competitors include BioSpecifics Technologies Corp, Eyenovia Inc, Ocular Therapeutix Inc, and Novartis AG. These companies also offer innovative solutions, products, and therapies for eye conditions, competing with Alimera Sciences Inc in the ophthalmic pharmaceutical market.

Alimera Sciences Inc is primarily active in the pharmaceutical industry.

The business model of Alimera Sciences Inc is focused on the research, development, and commercialization of ophthalmic pharmaceuticals. The company specializes in offering innovative treatments for retinal diseases, primarily diabetic macular edema (DME), a leading cause of vision loss. Alimera Sciences Inc primarily operates through its flagship product, ILUVIEN, which is a sustained-release intravitreal implant designed to deliver a continuous, low-dose of medication to the retina over an extended period. By providing long-lasting therapies, Alimera Sciences Inc aims to improve patient outcomes and reduce treatment burdens. With a devoted focus on retinal diseases, the company continues to expand its portfolio and enhance the quality of life for individuals with vision impairments.

Alimera Sciences KGV ir -21,11.

Alimera Sciences KUV ir 1,32.

AlleAktien kvalitātes vērtējums Alimera Sciences ir 5/10.

gaidāmā Alimera Sciences apgrozījums ir 108,13 milj. USD.

gaidāmā Alimera Sciences peļņa ir -6,77 milj. USD.

Alimera Sciences Inc is a biopharmaceutical company based in Georgia that specializes in the development and commercialization of therapies for eye diseases. The company was founded in 2003 and has since built various collaborations and partnerships with other companies. Alimera Sciences specializes in the development of medications for eye diseases, particularly Diabetic Macular Edema (DME) and Uveitis. The company's flagship product is ILUVIEN®, an intravitreal implant that continuously releases the glucocorticoid fluocinolone acetonide to slow the progression of vision loss. ILUVIEN® was approved in the United States in 2012 and has been on the market in Europe since 2013. Alimera Sciences Inc. serves a rapidly growing market as diabetic retinopathy and age-related macular degeneration (AMD) increasingly lead to significant impairments in vision. However, treating diabetic retinopathy and AMD is very challenging, and there are concerns about the safety and effectiveness of existing therapies. Alimera Sciences' business model is based on developing and bringing to market innovative medications and therapies that address the gaps in existing treatment options. The company works closely with other companies and research institutions to develop new technologies and treatment approaches. Alimera Sciences has established several marketing partnerships in various countries to distribute its products worldwide. The company has entered into strategic partnerships with major pharmaceutical companies such as Bausch + Lomb, Brill Pharma, and Mundipharma to enable broader marketing of ILUVIEN®. The company has also focused on researching and developing new technologies and therapies to harness the potential in other eye diseases, such as Uveitis. The company recently launched a novel antiviral therapy for Uveitis, which is still in the clinical trial stage. Alimera Sciences also maintains a pipeline of drugs in various stages of development to expand its portfolio of eye therapies. Alimera Sciences has experienced significant growth in recent years. The company achieved a net revenue of $51 million in 2019 and expects further growth in the coming years through the introduction of new products and expansion of its geographical reach. Overall, Alimera Sciences is a biopharmaceutical company specializing in the development and commercialization of therapies for eye diseases. The company has developed an innovative portfolio of products and technologies tailored to the needs of the rapidly growing market. Alimera Sciences has established strategic partnerships to facilitate the global marketing of its products. The company maintains a strong pipeline of drugs in various stages of development aimed at further closing the gaps in existing treatment options.

Alimera Sciences izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Alimera Sciences vai uzņēmums nedod dividendes.

Alimera Sciences ISIN ir US0162592028.

Alimera Sciences WKN ir A2PVHE.

Alimera Sciences simbols ir ALIM.

Pēdējo 12 mēnešu laikā Alimera Sciences maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Alimera Sciences plāno maksāt dividendes 0 USD apmērā.

Alimera Sciences pašreizējā dividendu rentabilitāte ir .

Alimera Sciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Alimera Sciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Alimera Sciences tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Alimera Sciences apmērā 0 USD, kas tika izmaksāta 26.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.08.2024..

Pēdējās dividendes izmaksa notika 26.08.2024..

Gadā 2023, Alimera Sciences izmaksāja 0 USD dividendes.

Alimera Sciences dividendes tiek izmaksātas USD.